ERBB2 and breast cancer: Until now, three ADCs have been approved by FDA for the therapy of certain types of cancer: gemtuzumab ozogamicin (acute myeloid leukaemia), brentuximab vedotin (Hodgkin's lymphoma and large-cell lymphoma), and T-DM1 (HER2-positive breast cancer) (31–33).